The IORE IRB

The Institute of Regenerative Education’s Institutional Review Board program offers a practical, structured way to protect regenerative medicine practices in an environment of increasing federal scrutiny.

Join the community

Generates Strong Defense Documentation

This creates a paper trail showing scientific intent, defined scope, and boundaries. In the event of an audit, investigation, or reimbursement dispute (e.g., related to skin substitutes or cellular products), you have documentation that your activities were conducted within a compliant research structure.

Stay Ahead of Federal Scrutiny

The IORE IRB provides a federally recognized, accredited framework specifically built for these real-world clinical uses. It demonstrates that your practice is conducting outcomes-focused research under independent oversight rather than unregulated innovation. This is particularly relevant for cash-pay and concierge models, which face the same federal rules as traditional practices.

Join the community

  • Turn Patient Outcomes Into a Long-Term Practice Asset

    Practices can systematically track patient outcomes for the exact modalities you work with (amniotic-derived biologics, exosomes, PRP/PRF, stem cell-adjacent therapies, and combination protocols). The data remains useful for your practice while potentially supporting future publications, presentations, or collaborations. Turning compliance into a long-term asset rather than just a cost center.

  • Separate Your Clinical Work From the Marketing Gray Zone

    One of the biggest regulatory risks in regenerative medicine is the perception (or allegation) that clinical activity is actually product-driven marketing. IRB participation helps separate legitimate clinical research and outcome tracking from promotional claims. This reinforces an evidence-based, patient-outcomes focus and reduces the risk of enforcement actions related to unsubstantiated marketing.

  • Build a Practice That Stays Defensible as Rules Tighten

    By clearly defining research intent, scope, and boundaries, the IRB framework helps align documentation, data use, and internal/external communication. This reduces ambiguity that can lead to compliance drift over time. It positions the practice as proactive and responsible in a field where regulatory expectations continue to tighten.

Bottom Line for Your Practice

In today’s environment, simply “doing what everyone else is doing” is no longer sufficient protection. The IORE IRB gives practices a defensible, documented pathway to continue innovating with biologics while demonstrating regulatory awareness and scientific rigor. It is especially well-suited for clinics using amniotic allografts, peptide therapies, and related regenerative products. Exactly the space where structured oversight can meaningfully reduce risk.

Join the community

Turn Patient Outcomes Into a Long-Term Practice Asset

The program includes enrollment in a retrospective, unbranded international registry focused on safety and efficacy across autologous, allogeneic, and peptide-based therapies.

Practices can systematically track patient outcomes for the exact modalities you work with (amniotic-derived biologics, exosomes, PRP/PRF, stem cell-adjacent therapies, and combination protocols). The data remains useful for your practice while potentially supporting future publications, presentations, or collaborations — turning compliance into a long-term asset rather than just a cost center.

Want to know more?

If you have any further questions or concerns send us a message

Dig Deeper

Important Context

The IORE IRB is not a product company or a manufacturer-controlled IRB. It is positioned as independent research and governance infrastructure designed specifically for regenerative clinicians. It covers the major modalities used in the field under one
unified framework.

Key Disclaimer

This is for educational and research purposes. Clinical application and ultimate regulatory compliance remain the responsibility of the licensed provider. It does not replace the need for sound medical judgment or guarantee immunity from all regulatory action (from the program itself).

Supports Real-World Evidence Generation Under Oversight

The program includes enrollment in a retrospective, unbranded international registry focused on safety and efficacy across autologous, allogeneic, and peptide-based therapies.

Federal Biologics Regulations

Federal biologics regulations apply regardless of state-level guidance. Many regenerative practices operate in a gray area with autologous/allogeneic products (amniotic membranes, exosomes, Wharton’s Jelly, PRP, peptides, etc.), especially for non-homologous uses. Operating outside a structured research framework can trigger heightened FDA scrutiny.

Participation Delivers

Structured safety-monitoring protocols, standardized consent language, defined data capture processes

Independent oversight that is reviewable and auditable